Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a CT scan replace invasive heart probes? new study aims to find out

NCT ID NCT06205810

Knowledge-focused Sponsor: CoreAalst BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will enroll 250 people with stable coronary artery disease to see how well a CT scan measures plaque buildup in heart arteries compared to an invasive ultrasound. Participants will undergo both tests as part of their standard care. The goal is to improve non-invasive diagnosis and monitoring of heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make CT scans a more reliable tool for assessing heart artery blockages, potentially reducing the need for invasive procedures.
What could go wrong
This is an observational study, not a treatment trial. It may not change current practice if the CT scan proves less accurate than expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Coronary Artery Disease with an epicardial stenosis of more than 50% of visual assessment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Epicardial stenosis more than 50% by visual assessment. Exclusion Criteria: 1. STEMI. 2. Hemodynamic instability. 3. Rapid atrial fibrillation, flutter or arrhythmia (HR \> 80 bpm). 4. Insufficient CCTA image quality. 5. Age \<18 years. 6. Chronic obstructive pulmonary disease. 7. Contraindication to adenosine. 8. NYHA class III or IV, or last known left ventricular ejection fraction \<30%. 9. Uncontrolled or recurrent ventricular tachycardia. 10. History of recent stroke (≤90 days). 11. Prior myocardial infarction. 12. History of ischemic stroke (\>90 days) with modified RANKIN score ≥ 2. 13. History of any hemorrhagic stroke. 14. Previous coronary artery bypass surgery. 15. Active liver disease or hepatic dysfunction, defined as AST or ALT \> 3 times the ULN. 16. Severe renal dysfunction, defined as an eGFR \<30 mL/min/1.73 m2. 17. BMI \>35 kg/m2. 18. Nitrate intolerance 19. Contra-indication to heart rate lowering drugs. 20. Unable to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OLV Hospital Aalst

    RECRUITING

    Aalst, Oost-Vlaanderen, 9300, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.